News | November 09, 2008

International Conference on Cell Therapy for Cardiovascular Disease Set for Jan. 13-16

November 10, 2008 - The Fifth International Conference on Cell Therapy for Cardiovascular Disease (IC3D) is a three-day program dedicated to cell-based therapies for cardiovascular repair and regeneration at the New York Academy of Medicine in New York City.

Abstracts are being requested from basic, translational, and clinical scientists who are interested in having data presented at IC3D. The deadline in Dec. 1. Content suitable for presentation at this meeting includes, but is not limited to, development of adult and embryonic stem cell lines; molecular signaling and cellular responses; models of acute and chronic myocardial injury; methods for application of stem cell products; preclinical and clinical studies of stem cell-based repair; engineered tissue including in vitro and in vivo studies; and imaging and other assessment methods.

Abstract submissions will be peer reviewed. Those accepted will be presented as posters at times that coincide with the themes of the IC3D program as they change each day.

For more information: www.crf.org/Cell_Therapy

Related Content

ProxiCor Extracellular Matrix Reduces Complications, Readmissions Following Pericardial Reconstruction
News | Stem Cell Therapies | April 19, 2019
Aziyo Biologics Inc. announced the publication of results from its landmark RECON study in the Journal of...
FDA Releases Final Guidances on Regenerative Medicine Therapies
News | Stem Cell Therapies | March 04, 2019
The U.S. Food and Drug Administration (FDA) recently finalized two guidance documents regarding regenerative medicine...
Heart Muscle Cells Created From Stem Cells Beat in Sync
News | Stem Cell Therapies | February 01, 2019
A team of Rutgers scientists have taken an important step toward the goal of making diseased hearts heal themselves – a...
FDA Clamps Down on Unapproved Stem Cell Therapies
News | Stem Cell Therapies | December 20, 2018
December 20, 2018 — The U.S.
Secant Introduces First Synthetic Regenerative Cardiovascular Graft for CABG
News | Stem Cell Therapies | January 17, 2018
Secant Group, in partnership with its sister company SanaVita Medical, announced new technology to advance...
News | Stem Cell Therapies | October 24, 2017
October 24, 2017 — Roche and Ncardia have reached a broad licensing agreement whereby Roche and its affiliate compani
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies | September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies | August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...

An example of porcine cartdiac stem cells. Photo from the University of Miami Miller School of Medicine.

 

News | Stem Cell Therapies | June 12, 2017
June 12, 2017 — Heart muscle is one of the least renewable tissues in the body, which is one of the reasons that hear
Overlay Init